These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37499279)

  • 1. Viral-vectored respiratory mucosal vaccine strategies.
    Jeyanathan M; Afkhami S; Kang A; Xing Z
    Curr Opin Immunol; 2023 Oct; 84():102370. PubMed ID: 37499279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.
    Jeyanathan M; Fritz DK; Afkhami S; Aguirre E; Howie KJ; Zganiacz A; Dvorkin-Gheva A; Thompson MR; Silver RF; Cusack RP; Lichty BD; O'Byrne PM; Kolb M; Medina MFC; Dolovich MB; Satia I; Gauvreau GM; Xing Z; Smaill F
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34990408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Sinha D; Yaugel-Novoa M; Waeckel L; Paul S; Longet S
    Antiviral Res; 2024 Mar; 223():105823. PubMed ID: 38331200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19.
    Afkhami S; Kang A; Jeyanathan V; Xing Z; Jeyanathan M
    Curr Opin Virol; 2023 Aug; 61():101334. PubMed ID: 37276833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
    Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience.
    Pilapitiya D; Wheatley AK; Tan HX
    EBioMedicine; 2023 Jun; 92():104585. PubMed ID: 37146404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?
    Brüssow H
    Microb Biotechnol; 2023 Jan; 16(1):3-14. PubMed ID: 36464938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
    Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
    Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H
    Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
    Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
    Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
    Chaparian RR; Harding AT; Hamele CE; Riebe K; Karlsson A; Sempowski GD; Heaton NS; Heaton BE
    J Virol; 2022 Aug; 96(15):e0068922. PubMed ID: 35862698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses.
    Morens DM; Taubenberger JK; Fauci AS
    Cell Host Microbe; 2023 Jan; 31(1):146-157. PubMed ID: 36634620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice.
    Cao K; Wang X; Peng H; Ding L; Wang X; Hu Y; Dong L; Yang T; Hong X; Xing M; Li D; Zhu C; He X; Zhao C; Zhao P; Zhou D; Zhang X; Xu J
    J Virol; 2022 Feb; 96(4):e0157821. PubMed ID: 34908443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
    White AD; Sibley L; Dennis MJ; Gooch K; Betts G; Edwards N; Reyes-Sandoval A; Carroll MW; Williams A; Marsh PD; McShane H; Sharpe SA
    Clin Vaccine Immunol; 2013 May; 20(5):663-72. PubMed ID: 23446219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.
    Yao Y; Lai R; Afkhami S; Haddadi S; Zganiacz A; Vahedi F; Ashkar AA; Kaushic C; Jeyanathan M; Xing Z
    J Infect Dis; 2017 Jul; 216(1):135-145. PubMed ID: 28531291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice.
    Ashhurst AS; Johansen MD; Maxwell JWC; Stockdale S; Ashley CL; Aggarwal A; Siddiquee R; Miemczyk S; Nguyen DH; Mackay JP; Counoupas C; Byrne SN; Turville S; Steain M; Triccas JA; Hansbro PM; Payne RJ; Britton WJ
    Nat Commun; 2022 Nov; 13(1):6972. PubMed ID: 36379950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.